Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2016-04-19 |
Amryt Pharma (UK) |
£10.0 million |
IP0 |
|
Rare diseases |
IPO |
2016-04-19 |
G-Therapeutics (Switzerland) |
€ 26 million |
series A financing round |
Gimv (Belgium) INKEF Capital (The Netherlands) Wellington Partners (UK) Life Science Partners (LSP) (The Netherlands) G-Therapeutics founders/management |
CNS diseases |
Series A financing round |
2016-04-18 |
AB Science (France) |
€ 12 million |
private placement |
|
Rare diseases - Hematological diseases - Neurodegenerative diseases |
Private placement |
2016-04-16 |
Oasmia Pharmaceutical (Sweden) |
SEK 45,5 million (€ 4.96 million) |
private placement |
institutional and qualified investors in Sweden |
Cancer - Oncology - Veterinary medicine |
Private placement |
2016-04-14 |
Geneuro (Switzerland) |
€ 33 million |
IPO |
Institut Mérieux (France) Servier (France) new international shareholders |
Autoimmune diseases - Neurodegenerative diseases |
IPO |
2016-04-14 |
Targedys (France) |
€5.8 million |
series A financing round |
Seventure Partners (France) NCI (France) Pontifax (Israel) |
Metabolic diseases |
Series A financing round |
2016-04-14 |
Molecular Partners (Switzerland) |
CHF 30,000,000 |
|
|
|
Private placement |
2016-04-12 |
Forbion Capital Partners (The Netherlands) |
€ 183 million |
fundraising |
European Investment Fund (EIF) Dutch Venture Initiative (DVI), KfW (Germany) regional investment agencies, pension funds, insurance companies, leading European family offices, Charles River Laboratories (USA) Knight Therapeutics (Canada) |
|
Fundraising |
2016-04-08 |
MedDay (France) |
€34 million ($38.5 million) |
series B financing round |
Edmond de Rothschild Investment Partners (EdRIP) (France) InnoBio (France) Large Venture - Bpifrance (France) Sofinnova Partners (France) |
Autoimmune diseases - Neurodegenerative diseases - Neurological diseases - Rare diseases |
Series B financing round |
2016-04-04 |
Anergis (Switzerland) |
CHF 5 Million |
financing round |
|
Allergic diseases - Inflammatory diseases - Respiratory diseases |
Financing round |
2016-04-02 |
Silence Therapeutics (UK) |
£27.3 million |
private placement |
|
|
Private placement |
2016-03-29 |
Gadeta (The Netherlands) |
€ 7 million |
series A financing round |
Baxalta Ventures (USA - MA) Utrecht Holdings (The Netherlands) Medicxi Ventures (Switzerland) founders and management |
Cancer - Oncology |
Series A financing round |
2016-03-24 |
Quantum Genomics |
€8.6 Million |
private placement, capital increase |
|
Cardiovascular diseases |
Private placement |
2016-03-24 |
Iterum Therapeutics (Ireland) |
$40 million |
series A financing round |
Frazier Healthcare Partners (USA - WA) Canaan Partners (USA - CA) Sofinnova Ventures (USA - CA) New Leaf Venture Partners (USA - CA) |
Infectious diseases |
Series A financing round |
2016-03-23 |
Polyphor (Switzerland) |
$3 million |
grant |
Cystic Fibrosis Foundation Therapeutics (USA - MD) |
Rare diseases - Genetic diseases |
Grant |
2016-03-22 |
Corvus Pharmaceuticals (USA - CA) |
|
IPO |
|
Cancer - Oncology |
IPO |
2016-03-22 |
Topas Therapeutics (Germany) |
€ 14 million |
series A financing round |
Evotec (Germany) Epidarex Capital (UK) EMBL Ventures (Germany)GIMV (Belgium) |
Autoimmune diseases |
Series A financing round |
2016-03-21 |
Atlantic Healthcare (UK) |
$24 million |
financing round |
Fullbrook Thorpe Investments (UK) LDC (the private equity division of Lloyds Banking Group plc), existing investors. |
Inflammatory diseases - Gastrointestinal diseases |
Restructuring |
2016-03-18 |
BerGenBio (Norway) |
NOK212 million (€ 22.51 million) |
capital increase |
existing shareholders, including Investinor AS and Meteva AS |
Cancer - Oncology |
Capital increase |
2016-03-15 |
Clinuvel (Australia) |
A$8.3 million (€ 5.62 million) |
private placement |
|
Ophtalmological diseases |
Private placement |